AUPH stock forecast, quote, news & analysis
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more
Aurinia Pharmaceuticals (AUPH) Stock Analysis: LUPKYNIS Momentum Meets Pipeline Promise
Key Takeaways
- Aurinia reported strong 2025 results with LUPKYNIS net product sales up 25% to $271.3 million and total revenue rising 20% to $283.1 million.
- Company guides for 2026 total revenue of $315–$325 million, signaling continued double-digit growth.
- Director-linked entities bought nearly 900,000 shares in late February and early March, boosting beneficial ownership to over 12 million shares.
- Aritinercept pipeline advances with one clinical study initiated and another planned for H1 2026 in autoimmune diseases.
- Analysts maintain a consensus Buy rating with an average price target of $17.00, implying upside from current levels.
- Cash position strengthened to $398 million, supporting share repurchases of $98.2 million in 2025.
Current Market Snapshot
Aurinia Pharmaceuticals (AUPH) stock has navigated volatile trading in recent weeks, reflecting broader biotech sector dynamics amid earnings digestion and insider activity. Shares have fluctuated within a 52-week range of $6.82 to $16.54, with year-to-date gains around 11% supported by robust LUPKYNIS demand. Market cap hovers near $1.9 billion, underscoring the company's position as a mid-cap player in autoimmune therapies. Investor sentiment balances strong commercial execution against pipeline risks, with recent price action showing resilience post-earnings despite some profit-taking. Trading volume has picked up on key news days, highlighting ongoing interest from institutional and retail participants alike.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of the platform’s most promising AI trading bots, drawn from hundreds of bots that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots employ advanced AI/ML models for pattern recognition, momentum capture, and risk-adjusted entries, with performance metrics like annualized returns up to +215%, win rates ranging 52–95%, and profit factors from 1.6 to 25.8. Examples include the AeroDefense ITA bot boasting +32% annualized return and 80% win rate on 60-minute timeframes, or multi-ticker strategies covering 25 assets in minerals, tech, and aerospace with +134% returns and 62% win rate. Only the top performers suited to current volatility earn a spot in this dynamic lineup, offering traders real-time signals for copy trading. Explore Trending AI Robots to see how these tools adapt to sectors like biotech and beyond.
Recent Developments Driving AUPH Price Action
Aurinia Pharmaceuticals (AUPH) has seen heightened volatility tied to pivotal corporate milestones over the past 30 days. The standout event was the February 26 release of Q4 and full-year 2025 financials, which showcased accelerating growth for flagship drug LUPKYNIS, approved for lupus nephritis. Total revenue hit $77.1 million in Q4 (up 29% year-over-year) and $283.1 million for the year (up 20%), driven by LUPKYNIS net product sales of $74.2 million quarterly (up 29%) and $271.3 million annually (up 25%). This momentum stemmed from expanded adoption, bolstered by clinical guidelines promoting early treatment.
Profitability surged with full-year net income of $287.2 million, fueled by a $173 million tax benefit from releasing a deferred tax asset valuation allowance, alongside operating cash flow tripling to $135.7 million. Balance sheet strength was evident with $398 million in cash and investments, enabling $98.2 million in share repurchases (12.2 million shares). Management's 2026 guidance—total revenue $315–$325 million (11–15% growth), LUPKYNIS sales $305–$315 million (12–16% growth)—signaled confidence but appeared conservative to some, prompting post-earnings selling despite beats on EPS ($1.53 vs. $0.22 expected) and revenue.
Pipeline progress added optimism: Aurinia initiated a clinical study for aritinercept, a dual BAFF/APRIL inhibitor, in one autoimmune disease, with another slated for H1 2026. This diversification beyond LUPKYNIS countered concerns over single-product reliance.
Insider confidence peaked as director Kevin Tang-linked limited partnerships acquired nearly 900,000 shares from February 27 to March 3 at mid-teens prices, lifting beneficial ownership above 12 million shares (about 9%). This $12+ million buying spree signaled strong internal conviction amid dips, spurring a rebound. Shares jumped over 6% on March 4 following disclosures.
Analyst reactions were mixed: consensus holds at Buy with $17 average target (high $21), though a December Leerink downgrade to Market Perform (target $16) lingered. No major rating shifts post-earnings, but coverage emphasized LUPKYNIS durability versus competition. Macro factors like biotech funding and autoimmune market expansion provided tailwinds, though volatility persisted on profit-taking and sector rotations. Overall, these catalysts linked robust fundamentals to price swings, with insider buys stabilizing sentiment.
2026 Outlook and Key Factors to Monitor
Aurinia enters 2026 with LUPKYNIS as a proven growth engine, guiding for $305–$315 million in sales amid expanding lupus nephritis diagnosis and treatment guidelines. Investors should track commercial traction, including patient adherence and payer dynamics, as the drug matures in a competitive landscape with emerging therapies. Pipeline execution on aritinercept—two studies launching H1—offers diversification into broader autoimmune indications; watch for safety data, enrollment, and early efficacy signals that could validate its BAFF/APRIL mechanism.
Financial health remains robust with $398 million cash, no long-term debt, and repurchase authorization, but monitor burn from R&D ramp-up and potential M&A. Regulatory hurdles, such as pediatric expansions or label updates, alongside industry trends like biologics shifts, pose risks. Competitive positioning versus generics or rivals, cost controls, and macro influences like reimbursement policies will shape trajectory. Balanced monitoring of these factors—commercial durability, pipeline milestones, and capital allocation—will inform strategic progress without assuming outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AUPH in upward trend: price rose above 50-day moving average on March 31, 2026
AUPH moved above its 50-day moving average on March 31, 2026 date and that indicates a change from a downward trend to an upward trend. In of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on March 31, 2026. You may want to consider a long position or call options on AUPH as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on March 31, 2026. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on April 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 183 cases where AUPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AUPH moved out of overbought territory on April 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where AUPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AUPH broke above its upper Bollinger Band on March 31, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.671) is normal, around the industry mean (26.681). P/E Ratio (7.754) is within average values for comparable stocks, (45.953). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.776). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (7.862) is also within normal values, averaging (325.679).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics
Industry Biotechnology